Prevention of atrial fibrillation with omega-3 fatty acids: A meta-analysis of randomised clinical trials

Heart

Volumn 97, Issue 13, 2011, Pages 1034-1040

  Liu, Tong ^a,b   Korantzopoulos, Panagiotis ^c   Shehata, Michael ^a   Li, Guangping ^b   Wang, Xunzhang ^a   Kaul, Sanjay ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; SOYBEAN OIL;

DRUG EFFICACY; DRUG RESPONSE; HEART ATRIUM FIBRILLATION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPPLEMENTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79958015920     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.215350     Document Type: Review

References (43)

1. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009;27:13-24.
2. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62-73.
3. Kourliouros A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009;157:243-52.
4. Naccarelli GV, Curtis AB. Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations. J Cardiovasc Pharmacol Ther 2010;15:244-56.
5. Moro C, Hernández-Madrid A, Matía R. Non-antiarrhythmic drugs to prevent atrial fibrillation. Am J Cardiovasc Drugs 2010;10:165-73.
6. Jadad A, Moore R, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
7. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
8. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-73. (Pubitemid 38993844)
9. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005;81:50-4. (Pubitemid 43073375)
10. Brouwer IA, Heeringa J, Geleijnse JM, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 2006;151:857-62.
11. Tatarskii BA. Alternative approaches to treatment of paroxysmal atrial fibrillation (in Russian). Vestn Ross Akad Med Nauk 2007;4:3-9.
12. Macchia A, Monte S, Pellegrini F, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008;64:627-34.
13. Patel D, Shaheen M, Venkatraman P, et al. Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J 2009;9:292-8.
14. Berry JD, Prineas RJ, van Horn L, et al. Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 2010;105:844-8.
15. Mariscalco G, Braga SS, Banach M, et al. Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 2010;61:643-50.
16. Macchia A, Varini S, Grancelli H, et al. The rationale and design of the FORomegaARD Trial: a randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J 2009;157:423-7.
17. Pratt CM, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J 2009;158:163-9. e1-3.
18. Kanorskii SG, Bodrikova VV, Kanorskaia IuS. Influence of perindopril, rosuvastatin, or omega-3 polyunsaturated fatty acids on efficacy of antirecurrence therapy with sotalol in patients with persistent atrial fibrillation (in Russian). Kardiologiia 2007;47:39-44.
19. Kumar S, Sutherland F, Rosso R, et al. Chronic fish oil ingestion in humans prevents atrial electrical remodeling and reduces susceptibility to atrial fibrillation. Heart Rhythm 2010;7:S108-9.
20. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723-8. (Pubitemid 40704512)
21. Heidt MC, Vician M, Stracke SK, et al. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg 2009;57:276-80.
22. Heidarsdottir R, Arnar DO, Skuladottir GV, et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356-63.
23. Saravanan P, Bridgewater B, West AL, et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010;3:46-53.
24. Erdogan A, Bayer M, Kollath D, et al. OMEGA AF study: polyunsatuated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. Heart Rhythm 2007;4:S185-6.
25. Bianconi L, Calò L, Mennuni M, et al. n-3 Poly-unsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicenter study. Europace 2011;13:174-81.
26. Sandesara C, Chung MK, Van Wagoner DR, et al. Fish oil to inhibit supraventricular arrhythmias after cardiac surgery: the FISH Trial. In: Heart Rhythm Society's 31st Annual Scientific Sessions. 12-15 May 2010, Denver, Late-Breaking Clinical Trials II. http://www.hrsonline.org/News/EPvn/#lbct.
27. Margos P, Leftheriotis D, Katsouras G, et al. Influence of n-3 fatty acids intake on secondary prevention after cardioversion of persistent atrial fibrillation to sinus rhythm. Europace 2007;9:iii51.
28. Nodari S, Triggiani M, Foresti A, et al. Use of N-3 polyunsaturated fatty acids to maintain sinus rhythm after conversion from persistent atrial fibrillation. A prospective randomized study. J Am Coll Cardiol 2010;55:A2.E14.
29. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010;304:2363-72.
30. Patel P, Dokainish H, Tsai P, et al. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 2010;21:1064-70.
31. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007;115:135-43. (Pubitemid 46136515)
32. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461-7. (Pubitemid 39585671)
33. Mas E, Woodman RJ, Burke V, et al. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res 2010;44:983-90.
34. Rennison JH, Van Wagoner DR. Impact of dietary fatty acids on cardiac arrhythmogenesis. Circ Arrhythm Electrophysiol 2009;2:460-9.
35. Anselmi A, Possati G, Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg 2009;88:326-33.
36. Liu T, Li L, Korantzopoulos P, et al. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70. (Pubitemid 351602110)
37. Metcalf RG, James MJ, Gibson RA, et al. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am J Clin Nutr 2007;85:1222-8. (Pubitemid 46740462)
38. Kromhout D, Gitay EJ, Geleijnse JM, et al. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26.
39. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9.
40. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61. (Pubitemid 19234807)
41. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8. (Pubitemid 46483662)
42. Anon. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
43. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.